Nicolas Mach - University of Geneva | 人才画像

基本信息

浏览量：46

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 139 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

Ravindra Uppaluri, Robert I Haddad,Yungan Tao,Christophe Le Tourneau,Nancy Y Lee, William Westra,Rebecca Chernock,Makoto Tahara, Kevin J Harrington, Arkadiy L Klochikhin,Irene Braña, Gustavo Vasconcelos Alves, Brett G M Hughes, Marc Oliva, Iane Pinto Figueiredo Lima,Tsutomu Ueda,Tomasz Rutkowski,Ursula Schroeder, Paul-Stefan Mauz,Thorsten Fuereder,Simon Laban,Nobuhiko Oridate,Aron Popovtzer,Nicolas Mach, Yevhen Korobko, Diogo Alpuim Costa, Anupama Hooda-Nehra,Cristina P Rodriguez,R Bryan Bell, Cole Manschot, Kimberly Benjamin,Burak Gumuscu, Douglas Adkins, KEYNOTE-68 Investigators

The New England journal of medicine (2025)

引用0浏览0WOS引用

Salvage Metastasis-Directed Therapy Versus Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases (PEACE V-STORM): a Phase 2, Open-Label, Randomised Controlled Trial

Piet Ost,Shankar Siva, Sigmund Brabrand,Piet Dirix,Nick Liefhooghe, François-Xavier Otte, Alfonso Gomez-Iturriaga,Wouter Everaerts,Mohamed Shelan, Antonio Conde-Moreno,Fernando López Campos,Alexandros Papachristofilou,Matthias Guckenberger,Marta Scorsetti,Almudena Zapatero, Ana-Elena Villafranca Iturre, Clara Eito, Felipe Couñago,Paolo Muto, Wim Duthoy,Nicolas Mach,Valérie Fonteyne,Daniel Moon,Kristian Thon,Carole Mercier,Vérane Achard,Karin Stellamans,Els Goetghebeur,Dries Reynders,Thomas Zilli

The Lancet Oncologyno. 6 (2025): 695-706

引用0浏览0WOS引用

Table 1 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

Rémi Vernet,Eugenio Fernandez,Denis Migliorini, Virginie Ancrenaz,Emily Charrier,Marie-Claude Belkouch,Olivier Von Rohr,Muriel Urwyler,Claudio De Vito, Jessica Renaux,Jean Villard,Olivier Rubin,Julien Grogg,Nicolas Mach

crossref（2024）

引用0浏览0引用

Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy

crossref（2024）

引用0浏览0引用

Figure 5 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

crossref（2024）

引用0浏览0引用

Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcomas: Looking Forward to What is Next

Brian Schulte,Nicolas Mach,Timothee Olivier

JOURNAL OF CLINICAL ONCOLOGYno. 20 (2024)

引用2浏览0WOS引用

Effectiveness of Fractionated Rituximab in Preventing Tumor Lysis Syndrome in Aggressive B-Cell Lymphoma: Insights from Real-Life Clinical Practice

Jasmine Mohamad,Antonin Bouroumeau,Thomas A. Mckee,Nicolas Mach,Kaveh Samii,Martine Chamuleau,Frank Stenner,Jerome Tamburini,Noemie Lang

CANCER REPORTSno. 10 (2024)

引用0浏览0WOS引用

Table 3 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

crossref（2024）

引用0浏览0引用

Table 5 from A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

crossref（2024）

引用0浏览0引用

A First-in-human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors

Remi Vernet,Eugenio Fernandez,Denis Migliorini, Virginie Ancrenaz,Emily Charrier,Marie-Claude Belkouch,Olivier Von Rohr,Muriel Urwyler,Claudio De Vito, Jessica Renaux,Jean Villard,Olivier Rubin,Julien Grogg,Nicolas Mach

CANCER RESEARCH COMMUNICATIONSno. 8 (2024): 2089-2100

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn